Ceftolozane Sulfate; Tazobactam Sodium Patent Expiration

Ceftolozane Sulfate; Tazobactam Sodium is Used for treating complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. It was first introduced by Cubist Pharmaceuticals Llc in its drug Zerbaxa on Dec 19, 2014.


Ceftolozane Sulfate; Tazobactam Sodium Patents

Given below is the list of patents protecting Ceftolozane Sulfate; Tazobactam Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zerbaxa US10028963 Methods for treating intrapulmonary infections Sep 07, 2032 Cubist Pharms Llc
Zerbaxa US10125149 Synthesis of cephalosporin compounds Aug 14, 2035 Cubist Pharms Llc
Zerbaxa US10376496 Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep 09, 2034 Cubist Pharms Llc
Zerbaxa US10420841 Ceftolozane antibiotic compositions Mar 14, 2034 Cubist Pharms Llc
Zerbaxa US10933053 Treating infections with ceftolozane/tazobactam in subjects having impaired renal function Sep 09, 2034 Cubist Pharms Llc
Zerbaxa US11278622 Ceftolozane antibiotic compositions Mar 14, 2034 Cubist Pharms Llc
Zerbaxa US7129232 Cephem compounds May 15, 2028 Cubist Pharms Llc
Zerbaxa US8476425 Tazobactam arginine compositions Sep 27, 2032 Cubist Pharms Llc
Zerbaxa US8685957 Tazobactam arginine compositions Sep 27, 2032 Cubist Pharms Llc
Zerbaxa US8906898 Solid forms of ceftolozane May 28, 2034 Cubist Pharms Llc
Zerbaxa US8968753 Ceftolozane-tazobactam pharmaceutical compositions Mar 14, 2034 Cubist Pharms Llc
Zerbaxa US9320740 Ceftolozane-tazobactam pharmaceutical compositions Mar 14, 2034 Cubist Pharms Llc
Zerbaxa US9724353 Methods for treating intrapulmonary infections Sep 07, 2032 Cubist Pharms Llc
Zerbaxa US9872906 Ceftolozane antibiotic compositions Mar 14, 2034 Cubist Pharms Llc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ceftolozane Sulfate; Tazobactam Sodium's patents.

Given below is the list recent legal activities going on the following patents of Ceftolozane Sulfate; Tazobactam Sodium.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 08 Feb, 2023 US10420841
Payment of Maintenance Fee, 4th Year, Large Entity 11 Jan, 2023 US10376496
Payment of Maintenance Fee, 8th Year, Large Entity 11 May, 2022 US8906898
Payment of Maintenance Fee, 4th Year, Large Entity 12 Apr, 2022 US10125149
Recordation of Patent Grant Mailed 22 Mar, 2022 US11278622
Patent Issue Date Used in PTA Calculation 22 Mar, 2022 US11278622
Email Notification 03 Mar, 2022 US11278622
Issue Notification Mailed 02 Mar, 2022 US11278622
Application Is Considered Ready for Issue 10 Feb, 2022 US11278622
Dispatch to FDC 10 Feb, 2022 US11278622



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳